Pioneer Valley Life Sciences Institute, University of Massachusetts, Amherst, Springfield, Massachusetts 01107, USA.
J Neurosci. 2012 Sep 12;32(37):12950-60. doi: 10.1523/JNEUROSCI.2017-12.2012.
Recent evidence has shown that glioblastoma stem-like cells (GSCs) can transdifferentiate into endothelial cells and vascular-like tumor cells. The latter pattern of vascularization indicates an alternative microvascular circulation known as vasculogenic mimicry (VM). However, it remains to be clarified how the GSC-driven VM makes a significant contribution to tumor vasculature. Here, we investigated 11 cases of glioblastomas and found that most of them consisted of blood-perfused vascular channels that coexpress mural cell markers smooth muscle α-actin and platelet-derived growth factor receptor β, epidermal growth factor receptor, and vascular endothelial growth factor receptor 2 (Flk-1), but not CD31 or VE-cadherin. This microvasculature coexisted with endothelial cell-associated vessels. GSCs derived from patients with glioblastomas developed vigorous mural cell-associated vascular channels but few endothelial cell vessels in orthotopic animal models. Suppression of Flk-1 activity and gene expression abrogated GSC transdifferentiation and vascularization in vitro, and inhibited VM in animal models. This study establishes mural-like tumor cells differentiated from GSCs as a significant contributor to microvasculature of glioblastoma and points to Flk-1 as a potential target for therapeutic intervention that could complement current anti-angiogenic treatment.
最近的证据表明,神经胶质瘤干细胞(GSCs)可以转分化为内皮细胞和血管样肿瘤细胞。后者的血管生成模式表明存在一种称为血管生成拟态(VM)的替代微血管循环。然而,GSC 驱动的 VM 如何对肿瘤血管生成做出重大贡献仍有待阐明。在这里,我们研究了 11 例神经胶质瘤,发现它们大多数由血液灌注的血管通道组成,这些通道共同表达壁细胞标志物平滑肌α-肌动蛋白和血小板衍生生长因子受体β、表皮生长因子受体和血管内皮生长因子受体 2(Flk-1),但不表达 CD31 或 VE-钙粘蛋白。这种微血管与内皮细胞相关的血管并存。源自神经胶质瘤患者的 GSCs 在原位动物模型中形成了活跃的壁细胞相关血管通道,但内皮细胞相关血管较少。Flk-1 活性和基因表达的抑制可消除 GSC 的转分化和血管生成体外,并抑制动物模型中的 VM。这项研究确立了由 GSCs 分化而来的壁样肿瘤细胞是神经胶质瘤微血管的重要贡献者,并指出 Flk-1 可能是一种潜在的治疗靶点,可补充当前的抗血管生成治疗。